About the Infectious Disease Treatment Market in China
Infectious diseases are caused by pathogenic microorganisms such as bacteria, parasites, fungi, or viruses. They can be transmitted from one person to another through direct or indirect contact. Anti-infective drugs are used to kill (cidal) or stop the growth (static) of infectious agents. Based on target organism, anti-infective drugs can be categorized into antibacterial, antifungal, antiviral, and antiparasitic.
Technavio’s analysts forecast the infectious disease treatment market in China to grow at a CAGR of 5.01% during the period 2016-2020.
Covered in this report The report covers the present scenario and the growth prospects of the infectious disease treatment market in China for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded, generic, and off-label drugs used to treat infectious diseases. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of the marketed drugs during the forecast period.
Technavio's report, Infectious Disease Treatment Market in China 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the Key vendorsoperating in this market.
Key vendors - F. Hoffmann-La Roche - Gilead Sciences - GSK - Johnson & Johnson - Merck - Pfizer
Market driver - Use of combination therapies - For a full, detailed list, view our report
Market challenge - Development of drug resistant strains - For a full, detailed list, view our report
Market trend - Emergence of interferon (IFN)-free therapies - For a full, detailed list, view our report
Key questions answered in this report - What will the market size be in 2020 and what will the growth rate be? - What are the key market trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by the key vendors? - What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Our reports have been used by over 10K customers, including:
242 pages •
By Asia Market Information & Development Company
• Aug 2021
China’s demand for Pneumonia Treatment Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer...
257 pages •
By The Business Research Company
• Dec 2020
Anti-Viral Drug Therapy Global Market Opportunities And Strategies To 2030: COVID-19 Implications And Growth provides the strategists, marketers and senior management with the critical information they need to assess the global anti-viral drug therapy market. Description: Where is the largest and fastest growing...
Heart Failure: Global Drug Forecast and Market Analysis to 2028 Summary Heart failure( HF) is a clinical syndrome where the heart is unable to meet the demands of the body with a sufficient blood supply.This can be due to structural or functional cardiac abnormalities which can be caused by unexpected...
Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2022 - Increasing Prevalence of Hypertension Drives Market Growth despite Weak Pipeline Summary Hypertension is a serious and common medical condition characterized by elevated blood pressure. It is commonly seen in the aging population, and in people with...
Non-Small Cell Lung Cancer Therapeutics in Asia-Pacific Markets to 2023 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market Summary Many countries are facing the challenge of an aging population, and there will be an increased number of people aged 60 and over – a high-risk age range...
74 pages •
By Infiniti Research Limited
• Jun 2016
About the Chronic Obstructive Pulmonary Disease (COPD) Drugs Market in China Chronic obstructive pulmonary disease (COPD) is a broad term that covers progressive lung diseases, including emphysema, chronic bronchitis, refractory (non-reversible) asthma, and some forms of bronchiectasis. It restricts airflow in the lungs and is characterized...
Gastric Cancer Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Increasing Prevalence and Launch of Targeted Therapies Summary Gastric cancer is characterized by the formation of malignant cells in the inner lining of the stomach, and is the fifth most common cancer globally. Due to its indolent nature it...
Colorectal Cancer Therapeutics in Asia-Pacific Markets to 2024 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market Summary Many countries are facing the challenge of an aging population, and there will be an increased number of people aged 50 and over – a high-risk...
Head and Neck Cancer Therapeutics in Asia-Pacific Markets to 2023 - Launch of Premium Immunotherapies and Increasing Prevalence to Drive the Market Summary Head and neck squamous cell carcinoma is the sixth most common cancer, and its incidence is growing. The term head and neck cancer (HNC) refers...
Heart Failure Therapeutics in Asia-Pacific Markets to 2024 - Growth Driven by Rising Geriatric Population and Increasing Uptake of Recently Launched Therapy Summary Heart failure (HF) is a life-threatening syndrome with substantial morbidity and mortality. There are more than 26 million people with...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.